Symptom-centric view
Product use in unapproved indication
Substances reporting Product use in unapproved indication disproportionately — ranked by ROR.
showing 8 of 8
| Substance ↓ | ROR [95% CI] | Reports | Category | Label |
|---|---|---|---|---|
tretinoin Retin-A · Atralin | 5.6 [5.1–6.1] | 524 | injectables | new |
semaglutide Ozempic · Wegovy | 3.5 [3.3–3.6] | 3,187 | glp-1 | new |
nicotinamide Niacinamide | 12.1 [10.7–13.6] | 296 | longevity | new |
minoxidil Rogaine · Loniten | 2.4 [2.2–2.5] | 1,173 | glp-1 | new |
| 2.1 [2.0–2.2] | 3,701 | algemeen | new | |
| 19.5 [18.9–20.2] | 3,839 | algemeen | new | |
| 12.0 [11.4–12.6] | 2,042 | algemeen | new | |
| 2.2 [2.2–2.3] | 16,393 | algemeen | new |
ROR = reporting odds ratio vs. the full FAERS corpus. A signal is not a cause. Source: openFDA (FAERS).